Evaluation of the ameliorative effects of immunosuppressants on crescentic glomerulonephritis in SCG/Kj mice

International Immunopharmacology

Volumn 8, Issue 9, 2008, Pages 1183-1189

  Saiga, Kan ^a   Yoshida, Minako ^b   Nakamura, Iwao ^a   Toyoda, Eriko ^a   Tokunaka, Kazuhiro ^a   Morohashi, Hirohisa ^a   Abe, Fuminori ^a   Nemoto, Kyuichi ^a   Nose, Masato ^b  

^a NIPPON KAYAKU CO LTD   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ANCA; Cyclophosphamide; Deoxyspergualin; Rapidly progressive glomerulonephritis; Therapy

Indexed keywords

15 DEOXYSPERGUALIN; CYCLOPHOSPHAMIDE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; EVALUATION; FEMALE; HEMATURIA; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; SYMPTOM; SYSTEMIC VASCULITIS; TREATMENT OUTCOME; UREMIA;

ANIMALS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BLOOD CELL COUNT; BLOOD UREA NITROGEN; BODY WEIGHT; CHURG-STRAUSS SYNDROME; FEMALE; GLOMERULONEPHRITIS; GUANIDINES; HEMATURIA; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MICE; MICE, INBRED STRAINS; PEROXIDASE; SURVIVAL ANALYSIS; URINALYSIS;

EID: 46349090777     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.04.005     Document Type: Article

References (31)

1. Kamesh L., and Harper L. Savage COS. ANCA-positive vasculitis. J Am Soc Nephrol 13 (2002) 1953-1960
2. Jayne D., Rasmussen N., Andrassy K., Bacon P., Tervaert J.W., Dadoniené J., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349 (2003) 36-44
3. Hoffman G.S., Kerr G.S., Leavitt R.Y., Hallahan C.W., Lebovics R.S., Travis W.D., et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 116 (1992) 488-498
4. Umeda Y., Moriguchi M., Kuroda H., Nakamura T., Iinuma H., Takeuchi T., et al. Synthesis and antitumor activity of spergualin analogues. I. Chemical modification of 7-guanidino-3-hydroxyacyl moiety. J Antibiot 38 (1985) 886-898
5. Amemiya H., Suzuki S., Ota K., Takahashi K., Sonoda T., Ishibashi M., et al. A novel rescue drug, 15-deoxyspergualin. First clinical trials for recurrent graft rejection in renal recipients. Transplantation 49 (1990) 337-343
6. Takeuchi T., Iinuma H., Kunimoto S., Masuda T., Ishizuka M., Takeuchi M., et al. A new antitumor antibiotics, spergualin: isolation and antitumor activity. J Antibiot 34 (1981) 1619-1621
7. Nemoto K., Hayashi M., Abe F., Nakamura T., Ishizuka M., and Umezawa H. Immunosuppressive activities of 15-deoxyspergualin in animals. J Antibiot 40 (1987) 561-562
8. Fujii H., Takada T., Nemoto K., Abe F., Fujii A., and Takeuchi T. In vitro immunosuppressive properties of spergualins to murine T cell response. J Antibiot 42 (1989) 788-794
9. Nishimura K., and Tokunaga T. Mechanism of action of 15-deoxyspergualin. I. Suppressive effect on the induction of alloreactive secondary cytotoxic T lymphocytes in vivo and in vitro. Immunology 68 (1989) 66-71
10. Nemoto K., Hayashi M., Ito J., Sugawara Y., Mae T., Fujii H., et al. Deoxyspergualin in lethal murine graft-versus-host disease. Transplantion 51 (1991) 712-715
11. Fujii H., Takada T., Nemoto K., Abe F., Fujii A., Talmadge J.E., et al. Deoxyspergualin, a novel immunosuppressant, markedly inhibits human mixed lymphocyte reaction and cytotoxic T-lymphocyte activity in vitro. Int J Immunopharmacol 14 (1992) 731-737
12. Morikawa K., Oseko F., and Morikawa S. The suppressive effect of deoxyspergualin on the differentiation of human B lymphocytes maturing into immunoglobulin-producing cells. Transplantation 54 (1992) 526-531
13. + B lymphocytes. Clin Exp Immunol 112 (1998) 495-500
14. Nadler S.G., Tepper M.A., Schacter B., and Mazzucco C.E. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp 70 family of heat shock proteins. Science 258 (1992) 484-486
15. Nadler S.G., Eversole A.C., Tepper M.A., and Cleaveland J.S. Elucidating the mechanism of action of the immunosuppressant 15-deoxyspergualin. Ther Drug Monit 17 (1995) 700-703
16. Waaga A.M., Krzymanski M., Ulrichs K., Treumer J., Oko A., and Muller-Ruchholtz W. In vitro analysis of the mode of action of immunosuppressive drug 15-deoxyspergualin. Arch Immunol Ther Exp 44 (1996) 155-163
17. Panjwani N., Akbari O., Garcia S., Brazil M., and Stockinger B. The HSC73 molecular chaperone: involvement in MHC class II antigen presentation. J Immunol 163 (1999) 1936-1942
18. Okada C., Toyoda E., and Nemoto K. Immunosuppressant deoxyspergualin-induced inhibition of cell proliferation is accompanied with an enhanced reduction of tetrazolium salt. J Antibiot 52 (1999) 45-51
19. Toyoda E., Hiratsuka M., Nemoto K., Yoneda M., and Odaka C. Immunosuppressant deoxyspergualin affects mitochondrial respiratory function in growing cells. J Antibiot 53 (2000) 633-636
20. Kawada M., Masuda T., Ishizuka M., and Takeuchi T. 15-Deoxyspergualin inhibits Akt kinase activation and phosphatidylcholine synthesis. J Biol Chem 277 (2002) 65-71
21. Hotta O., Furuta T., Chiba S., Tomioka S., and Taguma Y. Immunosuppressive effect of deoxyspergualin in proliferative glomerulonephritis. Am J Kidney Dis 34 (1999) 894-901
22. Birck R., Warnatz K., Lorenz H.M., Choi M., Haubitz M., Grünke M., et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six months open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 14 (2003) 440-447
23. Kinjoh K., Kyogoku M., and Good R.A. Genetic selection for crescentic formation yields mouse strain with rapidly progressive glomerulonephritis and small vessel vasculitis. Proc Natl Acad Sci U S A 90 (1993) 3413-3417
24. Kinjoh K., Good R.A., Nemoto K., Falk R.J., and Jennette J.C. SCG/Kj mice develop crescentic glomerulonephritis (CGN), vasculitis and MPO-specific ANCA. Clin Exp Immunol (Suppl 1) 101 (1995) 53
25. Miyazawa S., Saiga K., Nemoto K., Mae T., and Hotta O. A repeat biopsy study in spontaneous crescentic glomerulonephritis mice. Ren Fail 24 (2002) 557-566
26. Neumann I., Birck R., Newman M., Schnülle P., Kriz W., Nemoto K., et al. SCG/Kinjoh mice: a model of ANCA-associated crescentic glomerulonephritis with immune deposits. Kidney Int 64 (2003) 140-148
27. Birck R., Newman M., Braun C., Neumann I., Nemoto K., Yard B., et al. 15-Deoxyspergualin and cyclophosphamide, but not mycophenolate mofetil, prolong survival and attenuate renal disease in a murine model of ANCA-associated crescentic nephritis. Nephrol Dial Transplant 21 (2006) 58-63
28. Walton E.W. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 34 (1958) 265-270
29. Lan H.Y., Zarama M., Nikolic-Paterson D.J., Kerr P.G., and Atkins R.C. Suppression of experimental crescentic glomerulonephritis by deoxyspergualin. J Am Soc Nephrol 3 (1993) 1765-1774
30. Diegel M.L., Nadler S.G., and Kiener P.A. In vivo administration of 15-deoxyspergulin inhibits antigen-presenting cell stimulation of T cells and NF-kappaB activation. Int Immunopharmacol 2 (2002) 1451-1464
31. Faurschou M., Sorensen I.J., Mellemkjaer L., Loft A.G., Thomsen B.S., Tvede N., et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35 (2008) 100-105